Two Women.jpg

Know Your PR+ Status

If your cancer is PR+, then Apristor could be an option for you.

Onward Clinical Trials

ONWARD are clinical research studies for breast, ovarian, and endometrial cancer patients who have metastatic disease.

Learn More About ONWARD >

Are You PR+?

Up to 70% of breast, ovarian, and endometrial cancers express progesterone receptor (PR). If your cancer is PR+,  Apristor could be an option for you.

Learn More About PR >

What Is Apristor?

Apristor (Onapristone extended release) is an orally-bioavailable investigational drug that is a full progesterone receptor antagonist.

Learn More about Apristor >

diverse_hands_2.jpg

Are You PR+?

Up to 70% of all breast, ovarian, and endometrial cancers express the progesterone receptor (PR) and are thus said to be PR+. Progesterone receptor is an oncogene that promotes tumorigenesis.

Selfie.jpg

What is Onward?

ONWARD are clinical research studies for breast, ovarian, and endometrial cancer patients who have metastatic disease.

shutterstock_150591119.jpg

What Is Apristor?

Apristor is an investigational drug, which means it is currently not FDA approved for the treatment of PR+ cancer. It is a small molecule drug that blocks progesterone receptor-mediated activation of pro-survival signaling pathways in cancer cells.